# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1...
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediate...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $885 price target.
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.